Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

International Murex Gets What It Wants

Executive Summary

The $234 million purchase of International Murex Technologies Corp. by Abbott Laboratories may seem like a pricey deal, but it isn't if one considers that the whole of Murex is worth more than the sum of its parts. Murex has no stellar technology, but rather a broad portfolio of niche tests in virology and infectious diseases. Abbott is interested in Murex' blood banking business, its rapid HIV diagnostic assay, its attractive patent portfolio, and its microtiter plate technology.
Advertisement

Related Content

Innogenetics' New Chief Speaks Out

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV000888

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel